2737274-49-4
Chemical Structure
IDOR-1117-2520
- CAS No.: 2737274-49-4
- Formula:C25H32N4O3
- Molecular Weight:436.55
InChIKey: RLAQKDLLSLGHQO-VWLOTQADSA-N
SMILES: CC(C1=CC=C([C@@](C2=CC(C3=NOC(C(C)(O)C)=N3)=CN=C2)(O)C4(CN(C4)C)C)C=C1)C
Biological Activity: IDOR-1117-2520 is an orally active, potent, selective and reversible CCR6 antagonist. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow (IC50 = 63 nM) and inhibits β-arrestin recruitment to human CCR6 (IC50 = 30 nM) in cells expressing recombinant human CCR6. IDOR-1117-2520 is found to be a substrate of P-gp/MDR1. IDOR-1117-2520 can be used in the research of autoimmune diseases and skin inflammation[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
IDOR-1117-2520 | 99.94% | IDOR-1117-2520 is an orally active, potent, selective and reversible CCR6 antagonist. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow (IC50 = 63 nM) and inhibits β-arrestin recruitment to human CCR6 (IC50 = 30 nM) in cells expressing recombinant human CCR6. IDOR-1117-2520 is found to be a substrate of P-gp/MDR1. IDOR-1117-2520 can be used in the research of autoimmune diseases and skin inflammation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Meyer EA, et al. Discovery of the Clinical Candidate IDOR-1117-2520: A Potent and Selective Antagonist of CCR6 for Autoimmune Diseases. J Med Chem. 2024 May 10. [Content Brief]
- [2]. Kulig P, et al. Efficacy of IDOR-1117-2520, a novel, orally available CCR6 antagonist in preclinical models of skin dermatitis. Br J Pharmacol. 2025 Aug;182(15):3452-3475. [Content Brief]
Keywords
